As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

President Trump has eliminated funding for programs aimed at ending the growing HIV epidemic among minority communities, ...

Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), Gilead Sciences ...

Funding cuts have shaken every state, but the South is acutely vulnerable when it comes to HIV, said Gregorio Millett, MPH, ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Businesses that are solid enough to perform well over extended periods, while consistently raising their payouts, are ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

A disruption in federal funds has jeopardized HIV testing and outreach in the U.S. South, and researchers warn of a ...

The Gilead team wanted to see if they could use Sundquist's insights about how to hinder viral replication to design HIV drugs with longer acting power for people living with HIV; while the ...